Fulcrum Therapeutics Stock Today
| FULC Stock | USD 7.28 0.16 2.15% |
Performance2 of 100
| Odds Of DistressLess than 12
|
Fulcrum Therapeutics is trading at 7.28 as of the 25th of April 2024, a -2.15% down since the beginning of the trading day. The stock's open price was 7.44. Fulcrum Therapeutics has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Fulcrum Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of July 2019 | Category Healthcare | Classification Health Care |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. The company has 62.15 M outstanding shares of which 2.26 M shares are currently shorted by private and institutional investors with about 2.73 trading days to cover. More on Fulcrum Therapeutics
Moving together with Fulcrum Stock
| 0.65 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
| 0.7 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
Moving against Fulcrum Stock
| 0.57 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.45 | ELYM | Eliem Therapeutics | PairCorr |
| 0.45 | CGC | Canopy Growth Corp Trending | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 20th of May 2024
Fulcrum Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Fulcrum Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Fulcrum Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Alexander Sapir | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Fulcrum Therapeutics report their recommendations after researching Fulcrum Therapeutics' financial statements, talking to executives and customers, or listening in on Fulcrum Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Fulcrum Therapeutics. The Fulcrum consensus assessment is calculated by taking the average forecast from all of the analysts covering Fulcrum Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Fulcrum Therapeutics' liquidity, profitability, solvency, and operating efficiency, Fulcrum Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Fulcrum Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fulcrum Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Fulcrum Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Fulcrum Therapeutics' financial leverage. It provides some insight into what part of Fulcrum Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fulcrum Therapeutics (FULC) is traded on NASDAQ Exchange in USA. It is located in 26 Landsdowne Street, Cambridge, MA, United States, 02139 and employs 76 people. Fulcrum Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 462.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fulcrum Therapeutics's market, we take the total number of its shares issued and multiply it by Fulcrum Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Fulcrum Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 62.15 M outstanding shares of which 2.26 M shares are currently shorted by private and institutional investors with about 2.73 trading days to cover.
Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26.
Check Fulcrum Therapeutics Probability Of Bankruptcy
Ownership AllocationFulcrum Therapeutics retains a total of 62.15 Million outstanding shares. The majority of Fulcrum Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fulcrum Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fulcrum Therapeutics. Please pay attention to any change in the institutional holdings of Fulcrum Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Fulcrum Ownership Details
Fulcrum Stock Price Odds Analysis
What are Fulcrum Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Fulcrum Therapeutics jumping above the current price in 90 days from now is about 87.51%. The Fulcrum Therapeutics probability density function shows the probability of Fulcrum Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.5602. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Fulcrum Therapeutics will likely underperform. Additionally, fulcrum Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Fulcrum Therapeutics to move above the current price in 90 days from now is about 87.51 (This Fulcrum Therapeutics probability density function shows the probability of Fulcrum Stock to fall within a particular range of prices over 90 days) .
Fulcrum Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Fulcrum Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fulcrum Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fulcrum Therapeutics' value.| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2023-09-30 | 1.3 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.2 M | |
| Logos Global Management Lp | 2023-12-31 | 1.2 M | |
| Vestal Point Capital Lp | 2023-12-31 | 1 M | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 975.3 K | |
| Deutsche Bank Ag | 2023-12-31 | 823.1 K | |
| Propel Bio Management Llc | 2023-12-31 | 750 K | |
| Rock Springs Capital Management Lp | 2023-12-31 | 727.7 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 666.6 K | |
| Ra Capital Management, Llc | 2023-12-31 | 11.6 M | |
| Fmr Inc | 2023-12-31 | 5.7 M |
Fulcrum Therapeutics Historical Income Statement
Fulcrum Therapeutics Income Statement is one of the three primary financial statements used for reporting Fulcrum's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Fulcrum Therapeutics revenue and expense. Fulcrum Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Fulcrum Therapeutics' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 3.2 M, whereas Depreciation And Amortization is forecasted to decline to about 1.9 M. View More FundamentalsFulcrum Stock Against Markets
Picking the right benchmark for Fulcrum Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Fulcrum Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Fulcrum Therapeutics is critical whether you are bullish or bearish towards Fulcrum Therapeutics at a given time. Please also check how Fulcrum Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Fulcrum Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Fulcrum Therapeutics Corporate Management
Elected by the shareholders, the Fulcrum Therapeutics' board of directors comprises two types of representatives: Fulcrum Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fulcrum. The board's role is to monitor Fulcrum Therapeutics' management team and ensure that shareholders' interests are well served. Fulcrum Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fulcrum Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rudolf MD | Founder | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Jeffrey Jacobs | Chief Officer | Profile | |
| Mel Hayes | Chief Officer | Profile | |
| Paul Bruno | Senior Development | Profile |
How to buy Fulcrum Stock?
Before investing in Fulcrum Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Fulcrum Therapeutics. To buy Fulcrum Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Fulcrum Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Fulcrum Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Fulcrum Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Fulcrum Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Fulcrum Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Fulcrum Stock please use our How to Invest in Fulcrum Therapeutics guide.
Already Invested in Fulcrum Therapeutics?
The danger of trading Fulcrum Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Fulcrum Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Fulcrum Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Fulcrum Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.